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overall survival was better for patients with cubilin positive 
tumors. We also found that the fraction of cubilin nega-
tive patients was significantly higher in the non-responding 
group (PFS ≤3  months) compared to responding patients 
(PFS >3 months).
Conclusions We show for the first time that tumoral 
expression of cubilin is a positive predictive marker for 
treatment of metastatic renal cell cancer patients with suni-
tinib and sorafenib.
Keywords Cubilin · Predictive marker · Renal cancer · 
Tissue microarray · Tyrosine kinase inhibitor
Introduction
Renal cell carcinoma (RCC) is highly resistant to chemo-
therapy and radiotherapy (Motzer et  al. 1996). Cytokine 
therapy (high-dose interleukin 2 (IL-2) and interferon-alpha 
(IFN-α) has been approved for the treatment of metastatic 
renal cell carcinoma (mRCC). IFN-α is the most frequently 
used cytokine and it achieves an objective response rate of 
7.5% and a median overall survival (OS) time of 13 months 
(Negrier et al. 1998).
The introduction of targeted therapy has changed the 
standard of treatment for mRCC. Tyrosine kinase inhibitors 
(TKI); sunitinib, sorafenib, pazopanib and axitinib, act by 
blocking essential biochemical pathways or proteins that 
are required for tumor cell growth and survival (Cho and 
Chung 2012).
Sunitinib and sorafenib, two common used TKIs, are the 
focus for this study. Both these agents target the receptors 
of vascular endothelial growth factor (VEGF) and plate-
let-derived growth factor (PDGF) (Escudier et  al. 2012). 
In the first-line setting in metastatic disease, the median 
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Purpose Tyrosine kinase inhibitors like sunitinib and 
sorafenib are commonly used to treat metastatic renal cell 
cancer patients. Cubilin is a membrane protein expressed 
in the proximal renal tubule. Cubilin and megalin function 
together as endocytic receptors mediating uptake of many 
proteins. There is no established predictive marker for met-
astatic renal cell cancer patients and the purpose of the pre-
sent study was to assess if cubilin can predict response to 
treatment with tyrosine kinase inhibitors.
Methods Cubilin protein expression was analyzsed in 
tumor tissue from a cohort of patients with metastatic renal 
cell cancer (n = 139) using immunohistochemistry. One 
hundred and thirty six of the patients were treated with 
sunitinib or sorafenib in the first- or second-line setting. 
Thirty of these were censored because of toxicity leading 
to the termination of treatment and the remaining (n = 106) 
were selected for the current study.
Results Fifty-three (50%) of the tumors expressed cubi-
lin in the membrane. The median progression-free survival 
was 8  months in patients with cubilin expressing tumors 
and 4 months in the cubilin negative group. In addition, the 
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progression-free survival (PFS) extends to 11 months for 
sunitinib and in the second line setting to 5.5  months for 
sorafenib in selected patients (Escudier et al. 2007; Motzer 
and A 2007).
Several prognostic factors are established for RCC 
patients like number of metastatic sites, time from diag-
nosis to treatment, Karnofsky performance status, hemo-
globin, white blood count, platelets count, lactate dehy-
drogenase, alkaline phosphatase and “corrected” serum 
calcium (Heng et  al. 2009; Manola et  al. 2011). Though, 
considering possible severe toxicity and the costs of TKIs 
there is a need of predictive factors to select which patients 
will gain from the treatment.
The majority of studies predicting effects of sunitinib 
treatment in mRCC patients are based on serum proteins. 
Tumor necrosis factor α (TNFα) and metalloproteinase-9 
(MMP-9) baseline levels were significantly increased in 
non-responders and significantly associated with reduced 
OS and time-to-progression (Perez-Gracia et  al. 2009). In 
a study of circulating, VEGF and neutrophil gelatinase-
associated lipocalin (NGAL) pre-treatment levels were 
significant predictors of PFS (Porta et  al. 2010). Tumoral 
molecular markers, such as HIF-1-α, CA9, Ki67, CD31, 
pVEGFR1, VEGFR1 and VEGFR2, pPDGFR-α and -β 
might predict a good response to sunitinib treatment (Dorn-
busch et al. 2013). Developing hypertension, a well-known 
side effect of sunitinib-therapy, was associated with signifi-
cantly longer OS and PFS in a study of 111 patients with 
mRCC (Szmit et al. 2012a).
Hypertension induced by sorafenib is also a factor for 
early response evaluation (Szmit et al. 2012b).
Fewer predictive markers studies have been published 
for sorafenib than for sunitinib. In one study, patients with 
higher baseline plasma levels of VEGF benefitted more 
from sorafenib in terms of PFS than those with low levels 
(Escudier et al. 2009). In another study, levels of circulat-
ing cell-free DNA (cfDNA) had in a small subset of mRCC 
patients no predictive value at baseline but during sorafenib 
treatment (Feng et al. 2013).
Sorafenib is also used to treat hepatocellular cancer 
(HCC) (Llovet et  al. 2008). Nine serum cytokines (angi-
opoietin-2 (Ang-2), follistatin, granulocyte colony stimu-
lating factor (G-CSF), hepatocyte growth factor (HGF), 
interleukin-8 (IL-8), leptin, PDGF-BB, platelet endothelial 
cell adhesion molecule-1 and VEGF) were measured in 30 
HCC-patients treated with sorafenib. PFS was significantly 
shorter in patients with high levels of Ang-2, G-CSF, HGF 
and leptin at baseline (Miyahara et al. 2011).
Cubilin (CUBN) is a high molecular weight endocytic 
receptor expressed in proximal renal tubule (Christensen 
and Verroust 2002). It is a membrane protein which inter-
acts with megalin, another endocytic receptor, in the proxi-
mal tubule for effective reabsorption of filtered proteins 
including albumin, transferrin, vitamin D-binding protein 
and other important plasma carriers (Christensen et  al. 
2013).
Cubilin is also found in several other epithelia including 
the visceral yolk sac and to a lesser extent the ileal and the 
uterine mucosa (Verroust and Kozyraki 2001).
While cubilin has no known function in cancer, it was 
identified as a potentially interesting protein through sys-
tematic researches within The Human Protein Atlas (http://
www.proteinatlas.org) internal database for proteins. It was 
selected for further studies based on highly specific expres-
sion patterns in normal kidney and renal cancers on both 
immunohistochemistry level and RNA level (Ponten et al. 
2011). We have recently demonstrated that expression of 
cubilin is highly specific for RCC and that loss of cubilin 
expression is associated with poor prognosis (Gremel et al. 
2017).
The aim with the present study was to explore the poten-
tial value of tumoral expression of cubilin as a predictive 
marker for TKI treatment in mRCC patients.
Materials and methods
Patients
In an attempt to overcome some of the reporting deficien-
cies inherent in tumor marker studies, we followed the 
REporting recommendations for tumor MARKer studies 
(REMARK) (McShane et  al. 2005) when compiling this 
manuscript.
The cohort consisted of 139 patients in seven Depart-
ments of Oncology in Sweden: Uppsala (n = 48), Göte-
borg (n = 36), Örebro (n = 19), Västerås (n = 12), Gävle 
(n = 11), Falun (n = 7) and Karlstad (n = 6). These patients 
were diagnosed with mRCC between 2006 and 2010. All 
the patients had a prior nephrectomy and were thereafter 
treated with various therapeutic agents: TKIs (sunitinib and 
sorafenib), mTOR inhibitor (temsirolimus), IFN-α and/or 
bevacizumab. The patients (n = 136) treated with sunitinib 
(registered dosing is 50 mg daily for 4 weeks followed by 
2 weeks rest) or sorafenib (registered dosing is 400 mg two 
times daily continuosly) in the first- or second-line setting 
were selected for the current study. Twenty of these had 
been treated with IFN-α before receiving a TKI.
Clinical data was collected, including the patient’s age, 
gender and histologic subtype (Table  1) as well as the 
length of treatment with sunitinib and sorafenib. Progres-
sion-free survival was calculated as the time from the start 
of treatment to the time of clinical and/or radiological pro-
gression, treatment discontinuation due to toxicity or end 
of follow-up. We also registered the OS calculated from the 
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diagnosis of mRCC. We defined the patients experiencing a 
PFS of ≤3 months as the non-responding group.
Tissue microarray (TMA) generation
TMA, immunohistochemistry and slide scanning were 
essentially performed in accordance to standards used in 
the Human Protein Atlas (http://www.proteinatlas.org) 
(Kampf et  al. 2012; Ponten et  al. 2011). In brief, corre-
sponding HE slides were examined and representative 
regions from the primary tumors selected for the TMA. 
For each patient, two cores (1 mm in diameter) containing 
tumor tissue were collected (except in one case where there 
was only enough material for one core) by punch biopsy 
and transferred to recipient paraffin blocks subsequently 
containing 277 cores. TMArrayer™ (Pathology Devices, 
Westminster, MD, USA) and the Beecher Instruments 
Manual Tissue Arrayer MTA-1 (Estigen OÜ, Tartu, Esto-
nia) were used for this procedure.
Immunohistochemical methods
Immunohistochemistry and slide scanning was performed 
at the Swedish Science for Life Laboratory (SciLifeLab) 
facilities in the Department of Immunology, Genetics, 
and Pathology at the Rudbeck Laboratory of Uppsala 
University. In brief, 4-μm TMA sections collected on 
SuperFrost Plus slides were prior to immunostaining 
deparaffinised in xylene, re-hydrated in graded alco-
hols, blocked for endogenous peroxidase, and subjected 
to heat-induced antigen retrieval. Automated IHC was 
performed using a LabVisionAutostainer 480S (Thermo 
Fisher Scientific, Runcorn, UK). Primary antibody 
towards cubilin (HPA004133, Atlas Antibodies, Stock-
holm Sweden) was validated for immunohistochemistry 
according to established criteria (Kampf et al. 2012). The 
antibody was diluted 1:125 in UltraAb Diluent (Thermo 
Fisher Scientific, Fremont, CA, USA) and applied to the 
slides for 30  min at room temperature. The slides were 
further incubated with the secondary reagent, an anti-rab-
bitmouse horse reddish peroxidase-conjugated UltraVi-
sion (Thermo Fisher Scientific, Runcorn, UK) for 30 min 
at room temperature. Following the washing steps, the 
slides were developed for 10 min using the avidin–biotin 
peroxidase staining technique (Vector elite; Vector Labo-
ratories, Burlingame, CA, USA), using 3.3-diaminobenzi-
dine as the substrate. The slides were then counterstained 
with Mayer’s haematoxylin for 5  min (Sigma–Aldrich, 
St.Louis, MO, USA) and coverslipped with Pertex (His-
tolabAB, Gothenburg, Sweden).
Slide scanning and evaluation of staining
To obtain high-resolution digital images, the IHC slides 
were scanned with a ×20 objective using the AperioS-
canScope XT Slide Scanner (Aperio Technologies, Vista, 
CA, USA).
The digital images were examined in duplicates on a 
colour-calibrated screen using ImageScope (Aperio, Vista, 
CA, USA). Staining in the live tumor cells was semi-
quantitatively evaluated by two observers, of which one 
pathology specialist (MN and AD) and disagreements were 
resolved by re-evaluation of the images. MN and AD did 
not know the patient’s information until they completed 
evaluation of staining. Two cellular compartments were 
annotated: cytoplasm and membrane. For the membrane 
staining, both intensity (circumference) and fraction of 
stained cells were categorically estimated using a scale of 
0–2 for the intensity (0 = negative = 0–10% of the cells cir-
cumference stained, 1 = incomplete = 11–80% of the cells 
stained, 2 = complete = 81–100% of the cells circumfer-
ence stained), respectively, 0–4 for the fraction (0 = 0–1%, 
1 = 2–25%, 2 = 26–50%, 3 = 51–75%, 4 = 76–100%).
The distribution of the results for the membranous 
expression is given in Table 2.
Representative examples of negative, incomplete and 
complete membranous staining and staining of normal kid-
ney are shown in Fig. 1.
Table 1  Clinical characteristics of renal cancer patients treated for 
metastatic disease with sunitinib or sorafenib in the first- or second-
line setting




Age at diagnosis, years
 Median (range) 62.5 (33–77)
Age at metastatic disease, years
 Median (range) 65 (34–84)
Histologic type, n (%)
 Clear cell 89 (84)
 Papillary 4 (4)
 Mixed phenotype 4 (4)
 Unknown 9 (8)
Local disease at diagnosis, n (%) 49 (46)
Metastatic disease at diagnosis, n (%) 57 (54)
Time to metastasis, years
 Median (range) 2 (0–18)
 Metastasis during first year, n (%) 20 (41)
 Metastasis after first year, n (%) 29 (59)
 Alive, n (%) 17 (16)
 Dead, n (%) 89 (84)
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Statistical methods
For statistical analysis, the combined immune score for 
a cellular compartment was calculated by addition of the 
intensity score and fraction score, with a resulting scale 
from 0 to 6 for membrane. For the membranous staining 
the combined immune score 0–1 was defined as negative 
tumors and score 2–6 as positive tumors.
Statistical analyses (Kaplan–Meier method, log-rank 
test) were performed using STATISTICA program (version 
2012). A two sided p value < 0.05 was defined as statisti-
cally significant. The survival statistics was amended with 
Cox proportional hazards method to establish the influence 
of any covariates or factors. Ordinary 2 × 2 tables were also 
used and resulting  Chi2-tests analyzed. From these tables 
sensitivity and specificity could be evaluated. As a measure 
of control logistic models were set up and evaluated both 
along classical and Bayesian lines.
Results
Patients and follow‑up
Seventy-seven patients were treated with sunitinib and 59 
with sorafenib. Sixteen of the 77 patients and 14 of the 59 
patients were excluded from analysis because of early side 
effects, which lead to the termination of treatment. The 106 
remaining patients were treated for a median of 7 months 
with sunitinib (n = 61) or sorafenib (n = 45) (range 
0.5–40 months). Twelve patients were still on treatment at 
the end of the follow-up time (Table 3).
There were 77 males and 29 females in this final patient 
cohort. The median age of diagnosis in this group of 
patients was 62.5 years (range 33–77). Patients with local-
ized disease at diagnosis (49 patients) were diagnosed with 
metastases 0–18  years later, median 2  years. Twenty of 
these 49 patients developed metastatic disease during the 
first year after diagnosis. Fifty-seven patients had meta-
static cancer already at diagnosis.
Median overall survival from the diagnoses of mRCC 
was 26.5  months (range 1–144  months). At the end of 
the study there were 17 patients still alive and 89 were 
deceased (Table 1). The mean length of follow-up available 
for the surviving patients was 33 months (range 8–84).
Cubilin expression
The primary end-point of the study was PFS (defined clini-
cally and/or radiologically) and the second OS in regard 
with cubilin expression. For cytoplasmic staining we found 
no correlations with the primary end point of the study 
(Fig. 2). For the membranous staining, we used the cut-off 
value for combined staining score described above, which 
resulted in 53/106 (50%) cubilin positive cases.
The PFS was significantly better in patients with cubilin 
expression (p = 0.0019, Fig. 3). We observed that patients 
with cubilin positive tumors were treated with sunitinib or 
sorafenib in median 8  months (range 1–40  months) com-
pared to cubilin negative patients having a median treat-
ment time of 4 months (range 0.5–34 months).
Patient gender or age at diagnosis of mRCC showed no 
correlation to the membranous expression of cubilin (p val-
ues of 0.36 and 0.05, respectively).
Patients with positive cubilin staining had a signifi-
cantly better OS (p = 0.00001, data not shown). The cubi-
lin positive group had a median OS of 36 months (range 
Table 2  Distribution of membrane staining results among primary 
tumors of renal cancer from patients treated for metastatic disease 
with sunitinib or sorafenib in first- or second-line setting
Intensity score Percentage 
stained (%)
Number of cases















Combined score Number of cases
Combined score (addition of 









Cubilin expression Number of cases
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7–144  months) while cubilin negative had a median of 
15 months (range 1–108 months).
When PFS was analyzed separately for sunitinib and 
sorafenib treated groups (two-sample survival analysis) 
it still resulted in significant differences for positive and 
negative expression of cubilin (p values of 0.02 and 0.03, 
respectively, log-rank test, Fig. 4).
The fraction of patients with cubilin negative tumors 
was significantly higher in the non-responding group 
(n = 28) compared to the other patients. PFS was dichoto-
mized along with cubilin expression and the 2 × 2 table 
gave a  Chi2 value of 4.85 with a p value of 0.028. The 
sensitivity amounted to 67.9% and the specificity to 
56.4%.
Discussion
The prognosis of mRCC is still very poor although 
advances in the oncological treatment have been made. 
Finding molecular targets for RCC has been an area for 
research in recent years. Sunitinib and sorafenib, two orally 
administered TKIs, are the first and most used targeted 
therapies for these patients. An important observation is 
that some patients who are treated with TKIs benefit much 
more than the median while others have no gain at all from 
the treatment (Motzer and A. 2007; Ratain et  al. 2006). 
With a predictive marker responders could be selected for 
therapy and unnecessary severe toxicity (Di Lorenzo et al. 
2011) could be reduced as well as costs of the medication.
Cubilin (gp280) is expressed in the intestinal epithelium 
and renal proximal tubule epithelium where it functions 
as a receptor for the complex cobalamine-intrinsic factor. 
At molecular level, it is a 460 kDa membrane protein with 
many potential binding sites for various ligands. Together 
with other proteins such as megalin, cubilin contributes to 
the internalization of clathrine-coated membrane pits and 
to the reabsorption of vitamin-carrier proteins, transferrin, 
hemoglobin etc (Verroust and Christensen 2002). TGF beta 
downregulates cubilin and is associated with aggressive-
ness in RCC (Gekle et al. 2003; Sjolund et al. 2011). We 
have recently demonstrated that cubilin has a prognostic 
role in RCC patients (Gremel et al. 2017).
Fig. 1  Representative images 
of the immunohistochemistry 
results for cubilin from primary 
renal cell carcinomas, from 
patients later treated for meta-
static disease with sunitinib or 
sorafenib in the first- or second-
line setting, demonstrating 
negative (a), incomplete (b) and 
complete (c) membranous stain-
ing in tumor cells and normal 
kidney (d). Magnification ×200
Table 3  Treatment characteristics for renal cancer patients treated 
for metastatic disease with sunitinib or sorafenib in the first- or sec-
ond-line setting
Treatment Total n = 136
Sunitinib, n (%) 77 (57)
Sorafenib, n (%) 59 (43)





Treated until progression/end of follow-up, n (%) 106 (78)
 Sunitinib 61
 Sorafenib 45
Median PFS, months (range) 7 (0.5–40)
 Sunitinib 8
 Sorafenib 6
Still under treatment, n (%) 12 (11)
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In the present study, we used a well-validated antibody 
to analyze the potential role of tumoral cubilin expression 
as a predictive marker for sunitinib and sorafenib treatment 
in mRCC patients.
Both sunitinib and sorafenib prevent tumor angiogen-
esis, tumor growth and metastasis by inhibiting receptors 
of VEGF and PDGF (Bergers et  al. 2003; Escudier et  al. 
2012). VEGF- and PDGF-receptors are overexpressed in 
clear cell RCC due to inactivation of the tumor-suppressor 
gene von Hippel-Lindau (VHL) in at least 60% of the cases 
(van der Veldt et al. 2008).
Markers for early evaluation of response are established 
for sorafenib as well as sunitinib treatment. Hypertension 
related to sunitinib or sorafenib treatment in patients with 
mRCC is associated with a better response and prolonged 
OS (Rixe et al. 2007; Szmit et al. 2012a, b). In a retrospec-
tive analysis of over 500 patients those who developed 
hypertension during sunitinib treatment had significantly 
Fig. 2  Progression-free sur-
vival for renal cancer patients 
treated for metastatic disease 
with sunitinib or sorafenib in 
the first- or second-line setting 
(n = 106), cubilin (−) versus 
cubilin (+) tumors, cytoplasm
Fig. 3  Progression-free sur-
vival for renal cancer patients 
treated for metastatic disease 
with sunitinib or sorafenib in 
the first- or second-line setting 
(n = 106), cubilin (−) versus 
cubilin (+) tumors, membrane
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longer PFS and OS compared to patients not developing 
hypertension (Rini et al. 2011). The median time to initia-
tion of antihypertensive treatment was 28  days calculated 
from the start of the sunitinib treatment (range 10–80 days) 
(Bono et al. 2011). Hand-foot skin reaction (HFSR) is one 
of the common adverse events in patients treated with 
sorafenib and develop early in the course of the treatment, 
the majority during the first cycle (Hutson et  al. 2010). 
In a cohort of over 700 patients treated with sunitinib or 
sorafenib, the presence of skin toxicity was associated with 
improved OS and PFS in the sunitinib subgroup. (Poprach 
et al. 2012).
Just few potential predictive biomarkers for sorafenib 
have been studied. In a study with cfDNA, levels in patients 
with mRCC (n = 18) were significantly higher than those in 
healthy controls (n = 10). Baseline levels of plasma cfDNA 
were not associated with response to sorafenib treatment 
but a significantly lower level, measured from week 8 to 
24  weeks, was found in patients with remission or stable 
disease than in those with progression (Feng et al. 2013).
Fig. 4  a Progression-free sur-
vival for renal cancer patients 
treated for metastatic disease 
with sunitinib in the first- or 
second-line setting (n = 61). b 
Progression-free survival for 
renal cancer patients treated 
for metastatic disease with 
sorafenib in the first- or second-
line setting (n = 45)
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The majority of the previous predictive marker studies 
in mRCC patients have focused on serum biomarkers for 
sunitinib treatment. Studying baseline levels of TNF-α 
and MMP-9 in 21 sunitinib-treated patients significantly 
increased levels in non-responders were measured (Perez-
Gracia et  al. 2009). Levels of these two proteins, which 
promote cancer development (Bergers et al. 2000; Harrison 
et  al. 2007), were significantly associated with a reduced 
time to progression (TTP) and OS. In another study serum-
VEGF and -NGAL were evaluated. NGAL is strongly 
expressed in inflammatory, pre-tumoral and neoplastic 
lesions and tightly correlated with MMP-9. High baseline 
levels predicted a higher relative risk of progression in 
mRCC patients (n = 85) treated with sunitinib (Porta et al. 
2010).
In a TMA-study like ours, with substantially fewer 
mRCC patients (n = 42), potential predictive markers for 
response to sunitinib treatment were investigated. Hypoxia-
inducible factor 1α (HIF-1α), CA9, CD31, pVEGFR1, 
VEGFR1 and VEGFR2, pPDGFRα and -β and Ki67 were 
all associated with sunitinib response. In addition, a high 
HIF-1α expression was positively correlated to a longer 
PFS and a low PDGFRα score to a longer OS. Furthermore, 
patients with a low CA9 score (n = 19) had a median OS 
of 22 months compared to patients with a high CA9 score 
(n = 9) with a median OS of 48 months (Dornbusch et al. 
2013). In another study, tumor expression of programmed 
death-1 ligand (PD-L1) was analyzed in advanced RCC 
patients receiving VEGF-targeted therapy (pazobanib or 
sunitinib). Both PFS and OS were significantly shorter in 
patients with increased tumor cell PD-L1 or PD-L1 plus 
tumor CD8-positive T cell counts (Choueiri et al. 2015).
In our study, we found that patients with membranous 
cubilin expression in their primary tumors experienced a 
greater clinical benefit from sunitinib and sorafenib treat-
ment in terms of a doubled PFS. Since different tyrosine 
kinase inhibitors function differently to some extent, it is 
possible that they require separate predictive markers. 
However, when analyzing sunitinib and sorafenib treated 
patients separately the difference in PFS remained sig-
nificant. These findings indicate that membranous cubi-
lin expression is a predictive factor for both sunitinib and 
sorafenib treatment. Whether cubilin’s predictive value 
extends to all TKIs remains to be investigated.
In addition to PFS, the OS was also significantly longer 
in patients with cubilin positive tumors compared to the 
patients with cubilin negative tumors. A plausible explana-
tion is that the gain in PFS is translated into a longer OS. 
However, several of the patients were treated with other 
therapeutic agents, which could contribute to the differ-
ence in OS observed between the groups. Moreover, cubilin 
expression might predict survival independent of treatment 
(Gremel et al. 2017).
Patients are usually evaluated both clinically and radi-
ologically after two months of treatment. In a subanalysis 
we focused on patients treated ≤3 months with sunitinib 
or sorafenib and regarded these patients as non-respond-
ers. Our study showed that a significantly higher fraction 
of patients in the non-responding group had cubilin nega-
tive tumors. More studies are needed to explore whether 
it is possible to better select the minor group of patients 
with no benefit at all. One possible strategy would be to 
combine cubilin membranous expression with another 
putative predictive marker.
This study has some limitations. Due to its retrospec-
tive design, known serum prognostic markers (lactate 
dehydrogenase, hemoglobin, calcium) could for many 
patients not be recalled. Therefore, we were unable to 
assess whether cubilin has any prognostic value besides 
from being a predictive marker. Furthermore, the tumor 
response was not on a regular basis evaluated accord-
ing to the Response Evaluation Criteria In Solid Tumors 
(RECIST) (Therasse et al. 2000).
We show for the first time that cubilin tumoral expres-
sion is of predictive value for treatment of mRCC 
patients, a strong association with PFS was observed. In 
addition, a significantly higher fraction of patients in the 
non-responding group had cubilin negative tumors. Fur-
ther studies are needed to investigate whether cubilin is 
a predictive marker for all TKIs. Another aim for future 
research is to more accurately delineate the non-respond-
ing group since a better selection is warranted before 
starting to use cubilin as a predictive marker in the clinic.
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